Skip to main content

Barcelona, June 15th, 2020.

iVascular SLU today announced the global launch of essential pro, the novel reliable DCB.

essential pro presents several platform improvements from its predecessor such as:

-Superior safety with fast deflation times due to an increase of the inflation channel and the availability of two different shafts.

-Better pushability due to an improved transition lumen structure that transmits the whole push to the distal shaft, and uniform transmission due to a new straight distal dual layer shaft design without welds.

-Improved visibility with metallic radiopaque markers

-Improved trackability due to Hydrax plus, iVascular proprietary hydrophilic coating technology. Hydrax plus is applied in the distal shaft, reducing friction during navigation.

essential pro is indicated for the dilatation of stenosis or coronary artery or bypass grafts occlusions, including small vessels, as well as for residual stenosis after treatment with balloon or endoprosthesis and pre- and post-dilation of coronary endovascular prosthesis.

Clinical studies

essential in small vessels

An observational, prospective and multicenter registry in small vessels. Baseline characteristics showed a very small diameter of reference (<2.5mm) and high-risk patients (56% diabetics) with only a 12.7% of bailout stenting. In this registry, essential shows a 4.2% TLF at 12-months as a primary endpoint and 9.9% MACE at 12-month as a secondary endpoint.

essential demonstrates to be a reliable alternative for small coronary vessels.

Rodés-Cabau J. Coronary Artery Disease. 29(6):477 481, September 2018

esentialisr Outcomes

esential ISR Outcomes

 

essential in stent restenosis

An investigator initiated, observational, prospective and multicenter study.

DES restenosis was treated in 67% of the cases and a 94% of DCB angiographic success was achieved with only 2 additional stenting.

In this study essential shows a 51.4% In-segment maximal area stenosis at 6-month as a primary endpoint and a 13.3% TLF at 24-month as a secondary endpoint. In this study, essential showed a good and sustained efficacy in the treatment of ISR (mostly of DES) maintained on the very long-term.

 

De La Torre Cardiovasc Revasc Med.2019 Jul 23. pii: S1553-8389(19)30433-6

 

For more information on this product visit essential pro